Until Labs
Until Labs is a San Francisco-based biotechnology company developing reversible cryopreservation technology to extend donor organ viability for transplantation, with a long-term vision of enabling whole-body medical hibernation for terminal patients.
- Company typePrivate
- Founded2021
- HeadquartersSan Francisco, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Until Labs does
Until Labs is a San Francisco-based biotechnology company developing reversible cryopreservation technology to extend the viability of donor organs for transplantation. The near-term application targets the US organ transplant market, where roughly 100,000+ patients are on waiting lists, approximately 46,000 receive organs annually, and about 11,858 organs fail to reach patients each year largely because of short viability windows (4-8 hours for hearts and lungs, 24-36 hours for kidneys). The long-term vision extends to whole-body medical hibernation for terminal patients awaiting breakthrough treatments, with organ-scale work positioned as a de-risking path toward that broader goal.
The core platform integrates four technology pillars: (1) novel cryoprotectant formulations designed using molecular dynamics simulations and machine learning to prevent ice formation while minimizing toxicity, (2) perfusion protocols that use the organ's own vascular network to deliver cryoprotectants and iron-oxide nanoparticles uniformly, (3) cooling hardware that achieves vitrification below -130°C where water turns to glass, and (4) volumetric rewarming using alternating magnetic field (AMF) coils. The Until Mark I Rewarming System produces a 900 kHz oscillating field at up to 40 kA/m while consuming under 4 kW of power, compatible with standard hospital electrical infrastructure. Key scientific milestones include the recovery of electrical activity from cryopreserved and rewarmed rodent neural tissue (June 2024) and the successful volumetric rewarming of a vitrified pig kidney (May 2026).
The company is pre-revenue and in the R&D phase. Its planned go-to-market is enterprise field sales targeting transplant centers and organ procurement organizations, with planned revenue streams from organ cryopreservation services (recurring) and longer-term technology licensing. Pricing is not publicly disclosed. As of September 2025, Until Labs had raised $100M+ in total funding, including a $58M Series A led by Founders Fund with Lux Capital and Field Ventures participating, and operates with an interdisciplinary team of approximately 40+ scientists, engineers, surgeons, and operations staff led by co-founders Laura Deming (CEO) and Hunter Davis Ozawa (CSO).
Until Labs firmographics
Firmographics- Name
- Until Labs
- Legal name
- Until Labs
- Website
- https://www.untillabs.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Until Labs is a San Francisco-based biotechnology company developing reversible cryopreservation technology to extend donor organ viability for transplantation, with a long-term vision of enabling whole-body medical hibernation for terminal patients.
- Ownership category
- akta.pro rank
Until Labs industry classification
Industry- Product category
- Organ Cryopreservation Technology
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Cold Chain, Cryopreservation & Biologics Storage/Handling Technologies (HLAAAJAN)
- akta.pro secondary industries
- Cold Chain Storage & Cryopreservation Services (LN2/Ultra-low) (HLAGAGAK), Sample Preparation, Storage & Cryogenics (Freezers, Cryovials, Cryostats) (HLAGAIAJ)
Keywords
Where Until Labs is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Until Labs business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Organ Cryopreservation Services: The company plans to generate revenue through organ cryopreservation products and services for transplant centers, enabling indefinite storage and rewarming of donor organs
- Technology Licensing: Long-term potential for licensing cryopreservation technology, protocols, and equipment to healthcare institutions
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Until Labs product offering
Product offeringCore offering
Until Labs is developing a reversible cryopreservation platform for human donor organs that combines novel cryoprotectant formulations, perfusion and surgical protocols, and custom cooling and rewarming hardware to vitrify organs at subzero temperatures without ice formation and revive them uniformly for transplant. The company's first commercial sub-product is the Until Mark I rewarming system, an alternating magnetic field device paired with iron-oxide nanoparticles that achieves hospital-compatible volumetric rewarming of vitrified organs.
Product overview
Until Labs offers a unified reversible cryopreservation platform centered on enabling indefinite storage and rewarming of donor organs for transplant. The core platform integrates novel cryoprotectant formulations, perfusion and surgical protocols, and cooling/rewarming hardware to safely vitrify and revive human organs. A key sub-product is the Until Mark I Rewarming System, an AMF-based volumetric rewarming device that uses iron-oxide nanoparticles and alternating magnetic fields to achieve rapid, uniform organ rewarming at hospital-compatible power levels. The company also applies its technology toward longer-term whole-body medical hibernation.
Differentiator
Problem solved
Functional benefit
Products and services
- Until Reversible Cryopreservation Platform An integrated technology platform for reversible cryopreservation of human donor organs that combines novel cryoprotectant formulations, perfusion and surgical protocols, and cooling and rewarming hardware to safely vitrify organs at subzero temperatures without ice formation and rewarm them uniformly for transplant. Intended for use by transplant centers and organ procurement organizations to extend organ viability from hours to weeks or months.
- Until Mark I Rewarming System A volumetric organ rewarming system built around an alternating magnetic field (AMF) coil that produces a 900 kHz oscillating field at up to 40 kA/m and 7 kW of coil loss. Iron-oxide nanoparticles are perfused through the organ's vasculature to generate uniform, rapid heat when exposed to the AMF field. Designed to be hospital-compatible and has demonstrated rewarming of a vitrified pig kidney at 50–73°C/min while consuming under 4 kW of power from standard electrical infrastructure.
Quantifiable outcome
- Kidney viability window extended from 24-36 hours to potentially weeks or months
- +2 more outcomes
Companies that use Until Labs
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
Until Labs technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature5 records
Until Labs partnerships and signals
Strategic signalScale indicators5 records
Recent moves6 records
Expansion highlights5 records
Until Labs competitors and assessment
Company assessmentDirect peers
- TransMedics Group: TransMedics commercializes the Organ Care System (OCS) for lung, heart, and liver — a normothermic perfusion platform that keeps donor organs alive during transport. It is the most advanced commercial competitor in extending organ viability and viability windows, directly addressing the same transplant-center pain point Until Labs targets.
- OrganOx: OrganOx developed the metra normothermic liver perfusion device, FDA-cleared and commercially used in transplant centers worldwide. Like Until Labs, it focuses on extending organ preservation and viability windows for transplant, making it a direct competitive peer in target market and use case.
- XVivo Perfusion: XVivo Perfusion provides machine perfusion and preservation solutions for lungs, hearts, livers, and kidneys (e.g., XPS, LS™, Kidney Perfusion). It targets the same transplant-center customers and overlaps directly with Until Labs' value proposition of extending organ viability.
- Paragonix Technologies: Paragonix commercializes FDA-cleared hypothermic preservation and transport devices for donor hearts, lungs, and kidneys (SherpaPak, LUNGguard, KidneyVault). It competes for the same transplant-center procurement budgets and addresses organ viability — a direct peer on technology approach and customer.
- Bridge to Life: Bridge to Life supplies clinical-grade organ preservation solutions (e.g., Belzer UW, IGL-1) and is a major incumbent in cold-storage solutions used by transplant centers. It is comparable to Until Labs in serving organ preservation workflows, though its technology (chemical cold storage) is adjacent rather than overlapping.
Emerging players
- Arigos Biomedical: Arigos Biomedical is developing high-subzero vitrification and cryogenic storage technology for organs, including acquired technology from 21st Century Medicine. It is one of the closest direct technology competitors to Until Labs' vitrification platform, though it remains at an earlier commercialization stage.
- Ossium Health: Ossium Health cryopreserves bone marrow and is developing cryopreserved cellular therapeutics from deceased donor tissue, using related cryobiology and GMP cryopreservation infrastructure. It is comparable as a peer applying cryopreservation to transplant-relevant biological materials.
Broad incumbents
- United Therapeutics: United Therapeutics is a public biotech that has invested heavily in xenotransplantation and anti-rejection technologies, including the acquisition of Sylvatica Biotech for organ cryopreservation capabilities. It is comparable as a broader incumbent pursuing organ supply solutions, with cryopreservation as one strategic pillar.
Others
- 21st Century Medicine: 21st Century Medicine pioneered whole-organ vitrification technology (notably rabbit kidney work published in Nature Communications), with technology later acquired by Arigos Biomedical. It is comparable as a historical scientific predecessor in the vitrification space underlying Until Labs' approach.
Regional players
- Global Transplant Solutions: Global Transplant Solutions distributes preservation and transplant-related supplies and devices to organ procurement organizations and transplant centers. It is comparable as a participant in the same transplant-center procurement ecosystem Until Labs targets, though it operates primarily as a distributor rather than a technology developer.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Until Labs social profiles
Digital presenceUntil Labs financial estimates
Financial estimateRevenue estimate
Valuation estimate
Until Labs leadership team
Management profileNumber of profiles
Profiles8 records
Until Labs funding detail
Funding detailFunding overview
Funding rounds2 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Until Labs M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Until Labs
What does Until Labs do?
Until Labs is developing a reversible cryopreservation platform for human donor organs that combines novel cryoprotectant formulations, perfusion and surgical protocols, and custom cooling and rewarming hardware to vitrify organs at subzero temperatures without ice formation and revive them uniformly for transplant. The company's first commercial sub-product is the Until Mark I rewarming system, an alternating magnetic field device paired with iron-oxide nanoparticles that achieves hospital-compatible volumetric rewarming of vitrified organs.
Is Until Labs a public or private company?
Until Labs is a private company. It is classified as venture growth investor backed and is currently operating.
When was Until Labs founded?
Until Labs was founded in 2021. It employs 51 to 100 people.
Where is Until Labs based?
Until Labs is headquartered in San Francisco, United States, in the North America region.
How does Until Labs make money?
Two revenue lines are on record. Organ Cryopreservation Services are the primary driver. The others are technology Licensing.
Who are Until Labs's main competitors?
Direct peers on record are TransMedics Group, OrganOx, XVivo Perfusion, Paragonix Technologies and Bridge to Life. Emerging players are Arigos Biomedical and Ossium Health. United Therapeutics is listed as a broad incumbent. 21st Century Medicine is listed as an others. Global Transplant Solutions is listed as a regional player.
Does Until Labs have an API?
No public API is recorded for Until Labs.
What industry is Until Labs in?
Until Labs's product category is Organ Cryopreservation Technology. Its primary akta.pro industry code is HLAAAJAN, Cold Chain, Cryopreservation & Biologics Storage/Handling Technologies, with a secondary code of HLAGAGAK, Cold Chain Storage & Cryopreservation Services (LN2/Ultra-low). Its NAICS code is 334510 and its SIC code is 3845.